Komodo Health builds data-driven maps to analyze healthcare data and patient journeys for enterprise customers. The company is not yet profitable and reported ARR of around $150 million as of March, according to Axios. In March 2021 it announced a $220 million Series E that valued the business at $3.3 billion. Recently Komodo cut 9% of its staff (78 people) and its CFO confirmed plans to depart at the end of the year. Co-founders said the restructuring is intended to make the company more capital efficient and positioned for a changing market, and they characterized the layoffs as "one and done." Sources say the company has been rumored to be pursuing an IPO, and the recent moves appear tied to preparing for the public markets. Komodo Health operates an enterprise technology platform built on its Healthcare Map, which uses AI and advanced analytics to track longitudinal patient journeys for over 325 million de‑identified patients. The company supplies clinical insights and workflow integrations for life sciences companies, health plans, providers, and patient advocacy groups. Komodo plans to use new funding to accelerate investment in its enterprise platform, application suite, and core data assets. Earlier this year the company acquired Mavens, a cloud computing firm for life sciences, and completed a Series D led by ICONIQ Growth. Komodo emphasizes a patient‑centric approach to connect individual patient encounters with large‑scale health outcomes and to reduce disparities in care. The company was founded in 2014 and has been recognized for its real‑world evidence work, including a 2020 Company of the Year award from Frost & Sullivan. Komodo Health operates a SaaS platform anchored by its Healthcare Map, which aggregates de‑identified longitudinal data on over 320 million patients and captures about 15 million new clinical encounters each day. The platform provides analytics for life sciences, payers, provider organizations, patient advocacy groups and other healthcare stakeholders. Komodo’s software is used by seventy healthcare organizations and counts 19 of the top 20 pharmaceutical companies among its clients. The company’s tools are positioned to model disease epidemiology, identify geographic disparities in care, and guide provider‑level interventions to improve outcomes. Komodo plans to use its recent funding to create new software offerings and accelerate expansion of the Healthcare Map. Financially, the company announced a $50 million Series C in the reported round.

Total raised

$470M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2022